Expansion Therapeutics Developments in Controlling DM1

Expansion Therapeutics is a medical research firm that was founded by Dr. Stock Rocklage. Recently, the firm in collaboration with other research institutions took part in fighting myotonic dystrophy. This condition is also known as DM1. Other research bodies that took part in this campaign include Sanofi Ventures, Novartis Venture Fund, Kleiner Perkins, 5 AM Ventures, Alexandria Venture Investments and RA Capital Management. Expansion Therapeutics are very committed to fighting this disorder in entirety. They recently added $55.3 million to their research kitty for ensuring that the effects of this disorder are curbed at an early stage.

 

DM1 is the causative agent of a condition called muscular dystrophy. This condition is prevalent in adults. It results from overproduction of RNAs in the human body. When these chemicals are in excess, they become toxic. This toxicity leads to DM1. DM1 is a severe condition as it affects the functioning of body systems. More than one system can become affected resulting in paralysis of the entire body. It is, therefore, a serious condition that should be controlled if possible.

 

Unfortunately, DM1 is genetically transmitted. This means that an individual can inherit the disorder from relatives. The disease is more serious with the subsequent generation. This shows that there is a need to find a solution to this ailment that affects unexpecting individuals. Currently, there is no cure for DM1. However, with the ongoing researches in firms such as Expansion Therapeutics, there is hope that the disorder will be controlled. Expansion Therapeutics is currently relying on the study conducted at the laboratory of Dr. Mathew Disney as the starting point of their analysis.

 

Dr. Scott Rocklage is one of the Founding Partners of 5 AM Venture Management LLC. He has worked in this firm for numerous years. Initially, Dr. Rocklage was a managing partner of the firm. He has held other high profile positions in multiple companies. From May 2016, Dr. Rocklage has been serving as the CEO of EPIRUS Biopharmaceutical Inc. He has also been the CEO and Amersham Health during his illustrious career in the medical field.

 

To learn more, visit http://5amventures.com/team/scott-m-rocklage-phd/.

Leave a Reply

Your email address will not be published. Required fields are marked *